Teva Pharmaceutical Industries Limited (TEVJF)

9,40 0,00 (0,00%) Alla chiusura: 09:36AM EST

Teva Pharmaceutical Industries Limited

124 Dvora Hanevi’a Street
Tel Aviv 6944020
Israel
972 3 914 8213
https://www.tevapharm.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 34.004

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Eliyahu Sharon Kalif	Executive VP & CFO	2,01M	N/D	1973
Mr. Eric Drape	Executive Vice President of Global Operations	1,91M	N/D	1962
Mr. Mark Sabag	Executive Vice President of International Markets Commercial	1,92M	N/D	1971
Mr. Richard D. Francis	President, CEO & Director	N/D	N/D	1968
Mr. Amir Weiss	Senior VP & Chief Accounting Officer	N/D	N/D	1977
Ran Meir	Head of Investor Relations	N/D	N/D	N/D
Mr. David M. Stark	Executive VP & Chief Legal Officer	N/D	N/D	1969
Kathleen Veit	Senior Vice President, Global Compliance & Ethics Officer	N/D	N/D	N/D
Ms. Vikki Conway	Acting Head of Global Human Resources	N/D	N/D	N/D
Mr. Kevin C. Mannix	Senior Vice President of Investor Relations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Governance aziendale

L'ISS Governance QualityScore di Teva Pharmaceutical Industries Limited al 28 novembre 2023 è 2. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.